Ionetix Corp / DE / 8-K

What Happened
Ionetix Corporation announced on May 26, 2026 that the U.S. Food and Drug Administration approved the company’s Abbreviated New Drug Application (ANDA) for Gallium Ga-68 gozetotide (PSMA-11). The company issued a press release about the approval, which was furnished as Exhibit 99.1 to the Form 8-K (Item 7.01 — Regulation FD Disclosure; Item 9.01 includes the exhibit).

Key Details

• FDA approval date announced: May 26, 2026.
• Product: Gallium Ga-68 gozetotide (PSMA-11).
• Filing: Press release furnished as Exhibit 99.1 to the Company’s Current Report on Form 8-K.
• Form 8-K items reported: Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits).

Why It Matters
FDA approval of an ANDA is a regulatory milestone indicating the agency has authorized the submitted abbreviated application for the specified product. For investors, this development can be material because it relates directly to Ionetix’s product portfolio and regulatory progress; the company’s press release and any future filings may provide further details on commercial plans, timing, and potential financial impact.